Why the names changed
The change came from a consensus process led by three large liver associations, with 236 panelists from 56 countries. The old terms had two problems: they defined the disease by what it was not, and they used words seen as stigmatizing. 74% of respondents thought the old names flawed enough to change; 61% found "nonalcoholic" stigmatizing and 66% "fatty". Agreement required a 67% supermajority, and an independent committee made the final choice of name and criteria. The panel kept steatohepatitis as a term, judging it an important concept of how the disease works.1
- Steatotic liver disease is the umbrella term for fat in the liver from any cause.
- MASLD requires liver fat plus at least 1 of 5 cardiometabolic risk factors.
- MetALD is a new category for people with MASLD who also drink more alcohol: 140 to 350 g a week for women and 210 to 420 g for men.
- Cryptogenic steatotic liver disease covers liver fat with no metabolic risk factor and no known cause.
Multisociety Delphi consensus, 2023.1
The authors describe the new names as widely supported and free of stigma, and expect them to improve awareness of the disease and the identification of patients who have it.1
What semaglutide did in ESSENCE
ESSENCE is a phase 3 trial of semaglutide 2.4 mg a week against placebo, published in the New England Journal of Medicine in 2025. It enrolled 1,197 people with MASH confirmed by liver biopsy and fibrosis of stage 2 or 3, two on semaglutide for every one on placebo, and is planned to run for 240 weeks. The first results, from 800 people at week 72, were:3
- MASH resolved without worse fibrosis: 62.9% on semaglutide, 34.3% on placebo.
- Fibrosis improved without worse MASH: 36.8% against 22.4%.
- Both together: 32.7% against 16.1%.
- Weight: down 10.5% against 2.0%.
The difference in MASH resolution was 28.7 percentage points, with a range from 21.1 to 36.2. Bodily pain scores did not differ between the groups, and stomach and gut side effects were more common on semaglutide.3 The Wegovy label approves the MASH use under accelerated approval, based on these improvements in MASH and fibrosis; keeping it may depend on a confirmatory trial showing clinical benefit.2
Liver fat itself
Liver fat can also be measured without a biopsy. In SURPASS-3 MRI, 296 adults with type 2 diabetes had liver fat measured by MRI before and after 52 weeks. Liver fat started at an average of 15.71% of the liver and fell by 8.09 percentage points on tirzepatide 10 or 15 mg, against 3.38 on insulin degludec.4 Fat on a scan is not the same as MASH on a biopsy, which also looks for inflammation and scarring.
Other GLP-1-based drugs in MASH
Tirzepatide was tested in the phase 2 SYNERGY-NASH trial, where MASH resolved without worse scarring in 44% to 62% of people across its doses, against 10% on placebo, at week 52.5 Pemvidutide, which acts on the GLP-1 and glucagon receptors, resolved MASH in 58% of people on its 1.2 mg dose at 24 weeks in a phase 2b trial.6 Both were phase 2 trials funded by the companies that make the drugs, and pemvidutide's was named IMPACT. Neither drug has an approved MASH use yet.
Sources
- Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;79:1542-1556. doi:10.1016/j.jhep.2023.06.003
- WEGOVY (semaglutide) injection prescribing information. Novo Nordisk; DailyMed, version 19, published June 30, 2026; sections 1 and 14.4. dailymed.nlm.nih.gov
- Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 2025;392:2089-2099. doi:10.1056/NEJMoa2413258
- Gastaldelli A, Cusi K, Fernández Landó L, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 2022;10:393-406. doi:10.1016/S2213-8587(22)00070-5
- Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH). N Engl J Med 2024;391:299-310. Funded by Eli Lilly; NCT04166773. doi:10.1056/NEJMoa2401943
- Noureddin M, Harrison SA, Loomba R, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet 2025;406:2644-2655. Funded by Altimmune; NCT05989711. doi:10.1016/S0140-6736(25)02114-2
Related analyses
What to eat on a GLP-1: the priorities of four medical societies, with a day you can build
Alcohol on a GLP-1: what the labels say, what counts as a drink, and what five studies found
Muscle loss on Zepbound and Wegovy: how much of the weight lost is fat, and how much is muscle
Wegovy side effects: how common each one is, when it peaks and how long it lasts
Log liver test results and weight together, so your doctor sees both trends side by side.
Open Dose Insider